
SYRE Stock Forecast & Price Target
SYRE Analyst Ratings
Bulls say
Spyre Therapeutics is attractive because its core IBD thesis is supported by strong monotherapy validation across SPY001, SPY002, and SPY003, with SPY001 showing 40% clinical remission at week 12 and the platform trial’s Part B moving ahead of expectations. The 3Q26 SPY072 setback in PsA and axSpA weakens rheumatology upside, but it does not materially impair the company’s main value drivers because TL1A still has stronger validation in IBD and the program is being repositioned into HS, where a pivotal study is planned for 2027. Financially, the company ended 3Q26 with $1.07B in cash and investments, later raised about $396MM net for pro forma cash of roughly $1.47B, supporting an expected runway into 2H29 while key catalyst readouts remain scheduled for 3Q27 and late 2027/early 2028.
Bears say
Spyre Therapeutics is a clinical-stage biotech facing substantial regulatory uncertainty, because accelerated approval paths may still require additional data, longer studies, or revised requirements that could delay or even prevent commercialization. Its prospects are also weakened by competitive pressure, since rival updates can materially affect sentiment and the company may fail to secure product labels with the features needed to gain traction in inflammatory bowel disease and other immune-mediated diseases. Financially, the business is dependent on capital markets to fund development and future commercialization, and an inability to raise adequate capital would threaten continued pipeline advancement despite its single-segment focus on biopharmaceutical development.
This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SYRE Analyst Forecast & Price Prediction
Start investing in SYRE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Spyre Therapeutics Inc (SYRE) Forecast
SYRE Analyst Forecast & Price Prediction
Start investing in SYRE
Order type
Buy in
Order amount
Est. shares
0 shares